TRACP水平监测在前列腺癌骨转移中的临床意义

张志宏; 张凯; 金石华; 孙国锋; 李宁忱; 那彦群

doi:10.13201/j.issn.1001-1420.2015.10.013

TRACP水平监测在前列腺癌骨转移中的临床意义

- 北京大学首钢医院, 北京大学吴阶平泌尿外科医学中心(北京, 100144)

详细信息

通讯作者: 张志宏,E-mail:zhangzhihongw2001@163.com

中图分类号: R737.25

收稿日期: 2015-01-05

Application of TRACP in predicting bone metastasis of prostate cancer

- Peking University Shougang Hospital, Peking University Wujieping Urology Center, Beijing, 100144, China

More Information

Corresponding author: ZHANG Zhihong, E-mail: zhangzhihongw2001@163.com

Received Date: 05 January 2015

摘要

摘要: 目的:通过研究抗酒石酸酸性磷酸酶(tartrate-resistant acid phosphatase, TRACP)在发生骨转移的前列腺癌患者血清中的变化,探讨其在前列腺癌发生骨转移过程中的临床意义。方法:以81例前列腺癌患者以及40例良性前列腺增生患者为研究对象,同时以40例健康青壮年男性作为对照,分为四组:前列腺癌骨转移患者组(A组,n=42),前列腺癌无骨转移患者组(B组,n=39),良性前列腺增生患者组(C组,n=40),健康对照组(D组,n=40)。应用双抗体夹心酶标免疫分析法测定患者血清标本中的TRACP水平,结合病理分级、Gleason评分、前列腺特异抗原(PSA)、碱性磷酸酶(ALP)、谷丙转氨酶(ALT)等进行统计学分析。结果:前列腺癌骨转移患者组的血清TRACP浓度明升高,与其他各组比较差异有统计学意义;血清TRACP浓度与PSA水平有较强的正相关性;ROC曲线下面积(AUC) 均大于ALP和ALT,且TRACP与PSA的ROC曲线交叉,提示对骨转移的诊断价值较高。结论:TRACP的检测对于前列腺癌发生骨转移具有更直接的诊断价值和预测价值,通过监测前列腺癌患者的血清TRACP水平,对了解前列腺癌的生长状态、判断病程进展、预测骨转移的发生具有重要的临床意义。
- 抗酒石酸酸性磷酸酶 /
- 前列腺癌 /
- 骨转移
Abstract: Objective:To investigate the clinical effect of tartrate-resistant acid phosphatase (TRACP) in prostate cancer bone metastasis.Method:We selected 81 prostate cancer patients, 40 benign prostatic hyperplasia (BPH) patients, and 40 healthy young males. They were divided into four groups:group A (prostate cancer patients with bone metastasis, n=42), group B (prostate cancer patients without bone metastasis, n=39), group C (BPH patients, n=40), group D (healthy young males as normal control group, n=40). The serum TRACP level was tested with the method of enzyme-linked immunosorbent assay (ELISA). The prostate cancer grade, Gleason score, prostate specific antigen (PSA), alkaline phosphates (ALP), alanine aminotransferase (ALT) were also studied statistically.Result:The serum TRACP level of prostate cancer patients with bone metastasis was significantly higher than the other patients and healthy males. The serum TRACP level had a strong positive correlation with PSA level. The area under the ROC curve (AUC) of TRACP was greater than ALP and ALT. The ROC curves of TRACP and PSA showed intersection, indicating that TRACP has a high diagnostic value in prostate cancer bone metastasis.Conclusion:TRACP has a high and direct value in the prediction and diagnosis of prostate cancer bone metastasis. These results highlight the clinical importance of TRACP level in evaluating the prostate cancer growth, disease progression, and prediction of bone metastasis.
- TRACP /
- prostate cancer /
- bone metastasis

HTML全文

参考文献(19)

[1]	Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. Cancer J Clin, 2010, 60(5):277-300.
[2]	顾方六. 我国良性前列腺增生和前列腺癌发病调查[J]. 北京医科大学学报,2000, 32(1):30-32.
[3]	孙颖浩. 我国前列腺癌的研究现状[J]. 中华泌尿外科杂志, 2005, 25(2):77-78.
[4]	Bubendorf L, Sch pfer A, Wagner U, et al. Metastatic patterns of prostate cancer:an autopsy study of 1,589 patients[J]. Hum Pathol, 2000, 31(5):578-583.
[5]	Coleman R E. Clinical features of metastatic bone disease and risk of skeletal morbidity[J]. Clin Cancer Res, 2006, 12((20 Pt 2):6243-6249.
[6]	Bokhorst L P, Zhu X, Bul M, et al. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening:trends over time in a European randomized trial[J]. BJU Int, 2012, 110(10):1654-1660.
[7]	Naya Y, Okihara K, Evans R B, et al. Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy[J]. Urology, 2005, 66(2):350-355.
[8]	Roodman G D. Mechanisms of bone metastasis[J]. N Engl J Med, 2004, 350(16):1655-1664.
[9]	Sapi E. The role of CSF-1 in normal physiology of mammary gland and breast cancer:an update[J]. Exp Bjol Med(Maywood), 2004, 229(1):1-11.
[10]	Brubaker K D, Corey E, Brown L G, et al. Bone morphogenetic protein signaling in prostate cancer cell lines[J]. J Cell Biochem, 2004, 91(1):151-160.
[11]	Thomas B G, Hamdy F C. Bone morphogenetic protein-6:potential mediator of osteoblastic metastases in prostate cancer[J]. Prostate Cancer Prostatic Dis, 2000, 3(4):283-285.
[12]	郦俊, 邹志鹏, 刘恩旸, 等. 前列腺癌的骨转移机制[J]. 国际肿瘤学杂志, 2010, 37(8):621-623.
[13]	刘荣, 路名芝, 谢绮. 前列腺癌中PSMA, PSCA的表达与病理分级、骨转移和预后的关系及临床意义[J]. 实用临床医学, 2012, 13(2):236-138.
[14]	甘洁良, 朱汉民. 抗酒石酸酸性磷酸酶的测定及临床意义[J]. 上海医学检验杂志, 1997, 12(1):31-32.
[15]	Partin A W, Mangold L A, Lamm D M, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium[J]. Urology, 2001, 58(6):843-848.
[16]	Abramowitz M C, Li T, Buyyounouski M K, et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer[J]. Cancer, 2008, 112(1):55-60.
[17]	D'Amico A V, Chen M H, Malkowicz S B, et al. Lower prostate specific antigen outcome than expected following radica prostatectomy in patients with high grade prostate and a prostatic specific antigen tevel of 4 ng/ml, or less[J]. J Urol, 2002, 167(5):2025-2030.
[18]	郭应禄主编. 前列腺增生和前列腺癌[M]. 北京:人民卫生出版社, 1998:175-242.
[19]	楼慧玲,陈巧聪. 前列腺特异性抗原及骨标志物检测对前列腺骨转移患者诊断的意义[J]. 中华老年医学杂志, 2012, 31(5):421-424.